https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38204 Wed 18 Aug 2021 09:53:13 AEST ]]> Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48347 Wed 15 Mar 2023 08:25:44 AEDT ]]> Erlotinib loaded chitosan nanoparticles: formulation, physicochemical characterization and cytotoxic potential https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37112 10 million patients with new cases diagnosed every year. The objective of this study was to prepare and evaluate erlotinib loaded chitosan nanoparticles for their anticancer potential. Also, to study the effect of various formulation variables on prepared nanoparticles using box-behnken design. Erlotinib loaded chitosan nanoparticles were prepared by ionic gelation method using the spray drying technique. It was found that batch SNP-9 has a maximum loading capacity (74.45 ± 0.34%) and entrapment efficiency (43 ± 0.57%) with a particle size 170.2 nm. Analysis of variance (ANOVA) was applied on the particle size, entrapment efficiency and % cumulative drug release to study the fitting and the significance of the model. The batch SNP-9 showed 89.46% and 40.12% drug release after 24 h in 0.1 N HCl and Phosphate Buffer (pH 6.8), respectively. The IC⁵⁰ value of SNP-9 evaluated on A549 Lung cancer cells was found to be 4.41 μM. The optimized formulation was found stable after the six-month study as no considerable transformation was detected. The optimized formulation released erlotinib slowly in comparison to the marketed tablet formulation. Erlotinib loaded chitosan nanoparticles were prepared successfully using spray drying technique with suitable particle size, entrapment efficiency, drug release. The synthesized and optimized nanoparticles were found to possess activity against cancer cells when evaluated in-vitro.]]> Thu 09 Dec 2021 11:02:22 AEDT ]]> Oligonucleotide therapy: an emerging focus area for drug delivery in chronic inflammatory respiratory diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48492 Mon 20 Mar 2023 12:13:02 AEDT ]]> Emerging trends in nanomedicine for topical delivery in skin disorders: current and translational approaches https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39655 Fri 17 Jun 2022 13:47:58 AEST ]]>